Characterization of Circulating T Cell Receptor Repertoire Provides Information about Clinical Outcome after PD-1 Blockade in Advanced Non-Small Cell Lung Cancer Patients

SIMPLE SUMMARY: Immune checkpoint blockers (ICBs) have demonstrated durable anti-tumor responses in advanced non-small cell lung cancer (NSCLC). Despite progress in development of new predictive biomarkers, such as PD-L1 expression, TMB, or MSI, there is still an urge for a better selection of patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Ning, Moreno-Manuel, Andrea, Calabuig-Fariñas, Silvia, Gallach, Sandra, Zhang, Feiyu, Blasco, Ana, Aparisi, Francisco, Meri-Abad, Marina, Guijarro, Ricardo, Sirera, Rafael, Camps, Carlos, Jantus-Lewintre, Eloísa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8231221/
https://www.ncbi.nlm.nih.gov/pubmed/34204662
http://dx.doi.org/10.3390/cancers13122950

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8231221/
https://www.ncbi.nlm.nih.gov/pubmed/34204662
http://dx.doi.org/10.3390/cancers13122950

Ejemplares similares